Ikarian Capital’s ProQR Therapeutics PRQR Stock Holding History

Ikarian Capital’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.37M	Buy	3,425,930 +1,933,701	+130%	+$3.18M	0.69%	42
2026 Q1	$2.42M	Hold	1,492,229	–	–	0.2%	91
2025 Q4	$3.01M	Buy	1,492,229 +600,000	+67%	+$1.4M	0.24%	86
2025 Q3	$1.9M	Buy	892,229 +24,160	+3%	+$52.8K	0.19%	103
2025 Q2	$1.77M	Buy	+868,069	New	+$1.41M	0.34%	70
2024 Q4	–	Sell	-483,583	Closed	-$880K	–	195
2024 Q3	$880K	Hold	483,583	–	–	0.12%	102
2024 Q2	$803K	Hold	483,583	–	–	0.14%	82
2024 Q1	$1.1M	Buy	483,583 +10,958	+2%	+$23.4K	0.12%	101
2023 Q4	$936K	Hold	472,625	–	–	0.09%	102
2023 Q3	$614K	Hold	472,625	–	–	0.07%	107
2023 Q2	$766K	Hold	472,625	–	–	0.12%	89
2023 Q1	$1.01M	Buy	472,625 +50,000	+12%	+$153K	0.23%	79
2022 Q4	$1.56M	Buy	+422,625	New	+$554K	0.38%	45

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Ikarian Capital's PRQR Position: Q2 2026 in Review

Ikarian Capital increased its ProQR Therapeutics (PRQR) stake by 130% in Q2 2026, buying an estimated $3.18M and bringing the position to 3,425,930 shares worth $6.37M. The position accounts for 0.69% of the portfolio, ranked #42.

Ikarian Capital first reported a position in PRQR in Q4 2022 and has held it in 13 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Ikarian Capital held 3,425,930 shares of ProQR Therapeutics worth $6.37M as of Q2 2026.
Ikarian Capital bought 1,933,701 ProQR Therapeutics shares in Q2 2026, an estimated $3.18M.
ProQR Therapeutics made up 0.69% of Ikarian Capital's portfolio in Q2 2026, its #42 holding.
Ikarian Capital first reported a position in ProQR Therapeutics in Q4 2022 and has held it in 13 quarters since.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.